Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;34(1):133-137.
doi: 10.1002/mds.27559. Epub 2018 Dec 10.

Utility and implications of exome sequencing in early-onset Parkinson's disease

Affiliations

Utility and implications of exome sequencing in early-onset Parkinson's disease

Joanne Trinh et al. Mov Disord. 2019 Jan.

Abstract

Background: Although the genetic load is high in early-onset Parkinson's disease, thorough investigation of the genetic diagnostic yield has yet to be established. The objectives of this study were to assess variants in known genes for PD and other movement disorders and to find new candidates in 50 patients with early-onset PD.

Methods: We searched for variants either within genes listed by the International Parkinson and Movement Disorder Society Task Force on Genetic Nomenclature or rare homozygous variants in novel candidate genes. Further, exome data from 1148 European PD patients (International Parkinson Disease Genomics Consortium) were used for association testing.

Results: Seven patients (14%) carried pathogenic or likely pathogenic variants in Parkin, PLA2G6, or GBA. In addition, rare missense variants in DNAJC13:p.R1830C and in PPM1K:p.Y352C were detected. SPG7:p.A510V and PPM1K:p.Y352C revealed significant association with PD risk (P < 0.05).

Conclusions: Although we identified pathogenic variants in 14% of our early-onset PD patients, the majority remain unexplained, and novel candidates need to be validated independently to better further evaluate their role in PD. © 2018 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; biomarker; lymphocyte activation gene-3.

PubMed Disclaimer

Conflict of interest statement

Relevant conflicts of interest/financial disclosures: The authors declare no conflict of interest.

Figures

FIG. 1.
FIG. 1.
Nominated novel pathogenic variants for EOPD. DNAJC13 p.R1830C (NM_015268, c.5488C>T) variant presents in affected mother (L-1452) and son (L-1451). (B) PPM1K homozygous p.Y352C (NM_152542, c.1055A>G) variant in eariy-onset patient. (C) Filtering criteria to identify novel candidates. AOO, age of onset; age, age of patient; GnomAD, genome aggregate consortium; ExAC, exome aggregate consortium; CADD, combined annotation dependent.

References

    1. Hedrich K, Hagenah J, Djarmati A, et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Arch Neurol 2006;63(6):833–838. - PubMed
    1. Kann M, Jacobs H, Mohrmann K, et al. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Ann Neurol 2002;51(5):621–625. - PubMed
    1. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 2000;342(21): 1560–1567. - PubMed
    1. Xu Q, Li K, Sun Q, et al. Rare GCH1 heterozygous variants contributing to Parkinson’s disease. Brain 2017;140(7):e41. - PubMed
    1. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5(6):525–535. - PubMed

Publication types

Substances